Everest Medicines is focused on four therapeutic areas: oncology, immunology, cardio-renal disease, and infectious disease. Each of these represents an area with significant unmet medical needs, a substantial number of patients, and a deep pipeline of innovative products globally. For each of our chosen therapeutic areas, we have assembled a world-class team with specific and relevant expertise. Our growing portfolio of product candidates is built on a foundation of potentially first-in-class or best-in-class assets.
We are committed to partnering with global biopharmaceutical companies to develop innovative medicines for patients in Greater China and emerging Asia Pacific markets. Our senior business development and alliance management team is based in New York, Boston, San Diego and Paris, which gives us global reach and local presence in key hubs of biopharmaceutical innovation. Our business development team works closely and seamlessly with our clinical development and commercial teams in China to address scientific, clinical, regulatory, intellectual property, commercial, and reimbursement considerations to identify assets that have significant commercial potential. We have completed 8 licensing transactions to date. Most of our in-licensed products and product candidates are the lead assets of our global partners, who have chosen Everest to help them realize the full potential of these assets in Greater China and other parts of Asia.
We have assembled a senior leadership team with an extensive track record of successfully executing on the clinical development of novel therapies and navigating the evolving regulatory environment for innovative medicines in China.
Under a strategic partnership announced in March 2020 we plan to will build global manufacturing capabtilities in the Jiashan National Economic and Technological Development Zone. Jiashan is an innovation-driven industrial ecosystem where we can enjoy efficient local manufacturing and research and development. Our facilities will be designed to comply with the U.S. FDA and the EMA good manufacturing practice(GMP)/good storage practice (GCP) standards to meet demands in both Asia and the global market.
